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Endometriosis is characterised by the growth of ectopic lesions at multiple locations outside the uterine cavity and may be
considered a collection of distinct but related conditions. The exact aetiology of endometriosis is still not clear although a role
for inflammation is increasingly accepted. We therefore investigated the inflammatory activity of eutopic tissue and that of the
matching ectopic lesions from different locations by measuring the genetic expression of inflammatory chemokines and cytokines.
The gene expression in matching eutopic and ectopic tissue was compared, as was the gene expression in lesions from different
locations. A significantly higher mRNA expression of the chemokines ENA-78 and RANTES and the cytokines IL-6 and TNF𝛼was
observed in endometriotic lesions of the rectovaginal septum (RVS) compared to that of matching eutopic tissue. Comparisons
across lesion locations showed a significantly higher expression of IL-6 and TNF𝛼 in the RVS compared to lesions from either the
ovaries or the peritoneum.These results show that the production of some inflammatory chemokines and cytokines is significantly
increased in the ectopic endometrial tissue compared to matching eutopic tissue. Furthermore, IL-6 and TNF𝛼 are produced in
significantly higher quantities in RVS lesions compared to other lesions.
1. Introduction
Endometriosis is defined as the presence of endometrial tis-
sue outside the uterine cavity. The most common symptoms
leading to a diagnosis are dysmenorrhoea, pelvic pain, and
reduced fertility [1]. It is a very prevalent disease affecting up
to 10% of the reproductive-aged female population [2].
The precise aetiology of endometriosis is not yet clear.
Currently, the most widely accepted theory is the implan-
tation theory: retrograde menstruation can result in viable
endometrial cells and fragments entering the peritoneal
cavity [3] and once attached [4], they promote a chronic
pelvic inflammatory response [5]. Retrograde menstruation
however cannot explain all cases, as endometriotic lesions
have been identified in diverse locations such as the brain [6].
It is broadly accepted however thatmost of the ectopic lesions
can be separated into three main regions: (i) ovarian, (ii)
rectovaginal septum (RVS), and (iii) peritoneum. Biochem-
ical and pathological differences between the lesions found
in these locations have led to suggestions that endometriosis
may represent a collection of related but distinct conditions
[7]. It is possible that the variability between these distinct but
related lesions is what contributes to the enigmatic nature of
the disease.
The contribution of inflammation to the progression of
endometriosis is increasingly being recognised. Endometri-
otics lesions that are established at ectopic sites secrete
chemokines which attract macrophages into the peritoneal
cavity, further stimulating the inflammatory response and
release of cytokines [8]. Significantly increased numbers of
activated macrophages have been identified in the peritoneal
fluid of women with endometriosis [9], as has an increased
concentration of various chemokines and cytokines. Sig-
nificantly elevated levels of epithelial neutrophil-activating
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peptide (ENA-78) [10],monocyte chemotactic protein (MCP-
1) [11], interleukin (IL)-8 [12], tumor necrosis factor (TNF)-𝛼
[13], IL-6 [14, 15], and regulated on activation normal T cell
expressed and secreted (RANTES) [12] have all been found in
the peritoneal fluid of patients with endometriosis. Underlin-
ing the inflammatory nature of the condition is the fact that
TNF𝛼 [16], ENA-78 [17], and IL-6 [18, 19] are also elevated in
the serumofwomenwith endometriosis. Less data is however
available on the inflammatory response of the lesion itself
and whether there is variability based on the type or lesion
location. A difference in the production of specific cytokines
may provide an insight into the inflammatory activity of
lesions that grow in different locations.
In order to gain a better understanding of this complex
disease and the differences that can occur between various
lesions, this study investigated the production of several
chemokines and cytokines in matching eutopic endometrial
and ectopic endometriotic tissue and compared their gene
expression levels in the three most common presentations of
the disease.
2. Patients and Methods
2.1. Sample Collection and Patient Data. Informed consent
was collected prior to surgery from all women included in
the study. Laparoscopic surgery was performed for the inves-
tigation of pelvic pain or infertility, and any endometriotic
lesions identified were removed and their location was noted.
Where possible, an endometrial biopsy was also collected
using a soft curette (Pipelle-de-cornier, Laboratoire CCD,
France). All tissue collected during the surgery was stored
in RNAlater (Invitrogen Life Technologies, Zug, Switzerland)
at −80∘C until further use. Exclusion criteria for the study
included prior or current infections, liver dysfunction, or
the use of hormonal treatments, including any hormonal
contraceptive or gonadotropin releasing hormone analogues
(GnRHa) within the past 3 months. All laparoscopies were
performed in the proliferative phase of the menstrual cycle.
Institutional review board approval was obtained from the
ethical committee prior to the commencement of the study.
After the informed consent was obtained and exclusion
criteria were satisfied, we collected eutopic endometrial
biopsies from 17 patients. A single matching ectopic lesion
was collected from 15 women, two lesions were collected
from another, and three lesions in the final case, resulting
in 20 ectopic lesions with matching eutopic samples. The
primary indication for surgery was dysmenorrhea for ten
of these women, pelvic pain for four women, and infertility
for the remaining three. The average age of the patients was
32.94 ± 1.454, range 24–41, and the body mass index (BMI)
was 23.39 ± 0.914, range 18.90–33.10.
For the further comparison of the mRNA expression
across ectopic sites additional lesions were collected from
another 23 patients to make a total of 40 patients. A
single lesion was collected from 34 patients, two lesions
were collected from five patients, and three lesions were
collected from one patient, resulting in a total of 47 ectopic
endometriotic lesions. In some cases the isolated mRNA was
insufficient to determine the concentration of all genes of
interest and as such 𝑛 values are included with eachmean and
SEM. The primary indication for surgery was dysmenorrhea
for 17 women, pelvic pain for another 14, and idiopathic
infertility for the remaining nine.The average age was 35.58±
1.265, range 22–58, and the BMI was 23.79 ± 0.811, range
18.00–47.30. No significant difference in either age or BMI
was observed in the three groups based on lesion location.
2.2. Determination of Gene Expression in Eutopic Endome-
trium and Ectopic Endometriotic Tissue. Approximately
30mg of tissue from both the eutopic endometrial biop-
sies and ectopic endometriotic lesions was excised and
homogenized in the FastPrep 120 tissue homogenizer (30
seconds at 4.0m/sec) in cell lysis buffer (Qiagen, Du¨sseldorf,
Germany). RNA isolation was performed with the RNAeasy
minikit (Qiagen) and after isolation the TurboDNase kit
(Ambion, Life Technologies, Zug, Switzerland) was used
for genomic DNase digestion. One microgram of the total
RNA was reverse transcribed in a 25 𝜇L reaction volume
with the Moloney murine leukemia virus (MMLV) reverse
transcriptase (Promega, Du¨bendorf, Switzerland) and ran-
dom primers. The resulting cDNA was diluted 1 : 20 and
the absence of genomic DNA was confirmed with a reverse
transcriptase control.
The quantitative real time polymerase chain reaction
(qPCR) was performed with the SYBR green Fast Advance
Master Mix (Qiagen) and a Rotor-Gene RG 2000 (Corbett
Research, NSW, Australia), under the following conditions,
95∘C for 5min, followed by 40 cycles of 95∘C for 5 second, and
60∘C for 10 seconds. Specificity of the reaction was confirmed
viamelt curve analysis and the product size was confirmed on
a 4% agarose gel.
The Genbank accession number and the primer sequen-
ces for all genes examined by qPCR are shown in Table 1.
2.3. Statistical Analysis. The most stable reference genes and
the optimal combination to provide minimal variability were
selected via the geNORM software program and a geometric
mean of the four reference genes selected was used to
normalise the expression of the genes of interest for both the
eutopic and ectopic tissue [20].The reaction efficiency of each
assay was determined via linear regression [21] and the fold
change calculated with the qBASEplus software (Biogazelle,
Zwijnaarde, Belgium).
The difference between the matched eutopic and ectopic
mRNA expression at different locations and the difference
between mRNA in different ectopic locations were deter-
mined by a one-way Analysis of Variance (ANOVA) test with
a post hoc Bonferroni’s multiple comparisons test between
selected groups. All values are presented as mean ± SEM and
all statistical analysis was performed with Graphpad Prism
5.0 and significance was set at a value of 𝑃 < 0.05.
3. Results
3.1. Cytokine mRNA Concentrations in Matching Eutopic and
Ectopic Endometrial Tissue. For the chemokines a one-
way ANOVA test confirmed a significant variation between
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Table 1: Primer sequences of the reference genes and genes of interest.
Cytokine Genbank accessionno.
Sense Antisense
GAPDH NM 002046 5󸀠-TGC ACC ACC AAC TGC TTA GC-3󸀠 5󸀠-GGC ATG GAC TGT GGT CAT GAG-3󸀠
ACTB NM 001101 5󸀠-CTG GAA CGG TGA AGG GTG ACA-3󸀠 5󸀠-AAG GGA CTT CCT GTA ACA ATG CA-3󸀠
YWHAZ NM 003406 5󸀠- ACT TTT GGT ACA TTG TGG CTT CAA -3󸀠 5󸀠-CGC CAG GAC AAA CCA GTA T-3󸀠
RPL13A NM 012423 5󸀠CCT GGA GGA GAA GAG GAA AGA-3󸀠 5󸀠-TTG AGG ACC TCT GTG TAT TTG TCA A-3󸀠
IL-6 NM 00600 5󸀠-GCA CTG GCA GAA AAC AAC CT-3󸀠 5󸀠-CAG GGG TGG TTA TTG CAT CT-3󸀠
IL-8 NM 000584 5󸀠-ACT GAG AGT GAT TGA GAG TGG AC-3󸀠 5󸀠-AAC CCT CTG CAC CCA GTT TTC -3󸀠
ENA-78 NM 02994 5󸀠-CTC CAA TCT TCG CTC CTC CAA-3󸀠 5󸀠-GGA GGC TCA TAG TGG TCA AGA G-3󸀠
TNF𝛼 NM 000594 5󸀠-GCC CAT GTT GTA GCA AAC CC-3󸀠 5󸀠-TAT CTC TCA GCT CCA CGC CA-3󸀠
MCP-1 NM 002982 5󸀠-GGG CAT TGA TTG CAT CTG GC-3󸀠 5󸀠-CTG CTC ATA GCA GCC ACC TT-3󸀠
PAPP-A NM 002581 5󸀠-AGT GGT ATC CTC ACC CTG CT-3󸀠 5󸀠-GTT GCA AAA GGC TCG GTT GT-3󸀠
RANTES NM 002985 5󸀠-CTG CTT TGC CTA TGC CC-3󸀠 5󸀠-TCG GGT GAC AAA GAC GAC TG-3󸀠
themRNA concentrations of the ectopic endometriotic tissue
with eutopic endometrial tissue for ENA-78 (𝑃 = 0.0039) and
RANTES (𝑃 = 0.0490), but not for MCP-1 (𝑃 = 0.1251)
or IL-8 (𝑃 = 0.7991) (Figure 1). A Bonferroni’s multiple
comparisons test was performed to compare themean of each
location against the eutopic mean. No significant difference
was observed for MCP-1 mRNA expression between the
eutopic tissue (0.107 ± 0.015, 𝑛 = 17) and the ovarian lesions
(2.751±1.943, 𝑛 = 8,𝑃 < 0.05), the peritoneal (0.590 ± 0.167,
𝑛 = 7, 𝑃 < 0.01) or the RVS (1.865 ± 0.712, 𝑛 = 4, 𝑃 < 0.01)
lesions (Figure 1(a)). For ENA-78 there was a significantly
stronger expression in the RVS lesions (5.905 ± 3.569, 𝑛 = 4,
𝑃 < 0.01) compared to the eutopic tissue (0.613 ± 0.250,
𝑛 = 17), but no difference was observed in lesions from either
the ovaries (0.811±0.290, 𝑛 = 8), or the peritoneum (1.444 ±
0.504, 𝑛 = 7) (Figure 1(b)). For IL-8 there was no significant
variation in the mRNA expression in either the peritoneum
(0.396 ± 0.114, 𝑛 = 8), the ovarian (0.409 ± 0.084, 𝑛 = 8),
or the RVS (1.574 ± 0.385, 𝑛 = 5) compared to the eutopic
tissue (3.979 ± 3.337, 𝑛 = 20) (Figure 1(c)). A significantly
higher expression of RANTES mRNA was observed in the
RVS (0.582 ± 0.264, 𝑛 = 5, 𝑃 < 0.05) compared to the
eutopic tissue (0.239 ± 0.0432, 𝑛 = 17), but not in either
the peritoneum (0.220 ± 0.030, 𝑛 = 5) or the ovarian tissue
(0.190 ± 0.045, 𝑛 = 8) (Figure 1(d)).
For the inflammatory cytokines a one-way ANOVA test
confirmed a significant variation between themRNAconcen-
trations in the eutopic tissue with the mRNA concentration
in the ectopic tissue for TNF𝛼 (𝑃 = 0.0014) and IL-6
(𝑃 < 0.0001) (Figure 2). A post hoc Bonferroni’s multiple
comparisons test indicated that TNF𝛼 mRNA expression in
both the peritoneal (1.939 ± 0.667, 𝑛 = 8, 𝑃 < 0.05) and the
RVS (3.128±1.608, 𝑛 = 4,𝑃 < 0.01) samples was significantly
higher than that observed for their matching eutopic tissue
(0.444 ± 0.106, 𝑛 = 17), although no difference was observed
with the ovarian lesions (0.291 ± 0.034, 𝑛 = 8) (Figure 2(a)).
For IL-6 therewas a significantly higher expression in theRVS
region (9.308 ± 3.714, 𝑛 = 5, 𝑃 < 0.0001), but not the ovaries
(0.689 ± 0.237, 𝑛 = 7) or the peritoneal region (0.667 ± 0.237,
𝑛 = 7) compared to the eutopic tissue (0.152 ± 0.091, 𝑛 = 17)
(Figure 2(b)).
3.2. Cytokine mRNA Concentrations of Ectopic Endometriotic
Lesions from Different Locations. A significant variation was
observed between the mRNA expression of TNF𝛼 (𝑃 =
0.0265) and IL-6 (𝑃 < 0.0001), amongst the endometriotic
lesions from different locations. A post-hoc Bonferroni’s
multiple comparisons test indicated that the TNF𝛼 mRNA
expression in the RVS (2.590 ± 1.357, 𝑛 = 5) was significantly
higher than in the ovarian lesions (0.813 ± 0.144, 𝑛 = 24,
𝑃 < 0.05), but not in the peritoneal lesions (1.711 ± 0.460,
𝑛 = 12). For IL-6 the mRNA expression in the RVS lesions
(10.150 ± 3.148, 𝑛 = 6) was significantly higher than the
expression in both the ovaries (1.260 ± 0.323, 𝑛 = 24, 𝑃 <
0.0001) and the peritoneum (1.211 ± 0.400, 𝑛 = 13, 𝑃 <
0.0001) (Figure 3).
In contrast no significant difference in mRNA expression
was observed for any of the four chemokines examined in this
study.MCP-1 expression in theRVS (1.700 ± 0.576, 𝑛 = 5)was
not significantly higher than either the ovarian (1.393 ± 0.632,
𝑛 = 25) or the peritoneal samples (0.814 ± 0.215, 𝑛 = 13),
whichwas also the case for ENA-78 (Peritoneal; 1.497 ± 0.465,
𝑛 = 13, ovarian; 2.988 ± 1.429, 𝑛 = 25, RVS; 4.822 ± 2.969, 𝑛 =
5), IL-8 (peritoneum; 1.548 ± 1.188, 𝑛 = 13, ovaries; 1.352 ±
0.471, 𝑛 = 25, RVS; 2.017 ± 0.543, 𝑛 = 6), and RANTES
(peritoneal; 0.288 ± 0.064, 𝑛 = 11, ovarian; 0.364 ± 0.054,
𝑛 = 22, RVS; 0.528 ± 0.222, 𝑛 = 6) (Figure 3).
4. Discussion
The study showed that the mRNA expression of the
chemokines ENA-78 and RANTES, as well as the inflamma-
tory cytokines TNF𝛼 and IL-6, was significantly increased in
the ectopic lesion compared to those in the matched eutopic
tissue in women with endometriosis. For IL-6, ENA-78, and
RANTES this increasewasmost significant in theRVS region,
whereas for TNF𝛼, it was in both the peritoneal lesions and
the RVS lesions. In addition, when compared across lesion
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Figure 1: Chemokine production in eutopic endometrium and matching ectopic endometriotic lesions from different locations. (a) No
significant difference was observed in the mRNA expression of MCP-1. (b) ENA-78 mRNA expression was significantly stronger in the RVS
lesions compared to its matching eutopic tissue. (c) No significant difference in IL-8 mRNA expression was observed between the eutopic
endometrium and the ectopic lesions from different locations. (d) RANTES expression was significantly higher in the RVS lesions compared
to the eutopic endometrium. All values are represented by mean ± SEM. ∗ < .05, ∗∗ < .01.
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Figure 2: Inflammatory cytokine mRNA expression in eutopic and matching ectopic endometriotic lesions from different locations. (a) The
mRNA expression of TNF𝛼was significantly higher in the peritoneal and RVS lesions compared to their matching eutopic endometrium. (b)
The mRNA expression of IL-6 was significantly higher only in the RVS lesions. All values are represented by mean ± SEM. ∗ < .05, ∗∗ < .01,
∗∗∗∗
< .0001.
locations IL-6 was the most highly expressed in the RVS
region compared to either the ovaries or the peritoneum.
The results suggest therefore that different inflammatory
proteins have separate roles in different lesions and under-
standing these roles may help to specifically target certain
presentations of endometriosis. In addition, the increased
production of many of these proteins by the RVS lesions
provides some molecular evidence towards the notion that
lesions developing in the RVS are strongly inflammatory.
Increased expression of chemokines by ectopic endome-
trial implants is an important early stage in the pathogen-
esis of endometriosis. Chemokines secreted by the ectopic
lesions stimulate the infiltration of macrophages that fur-
ther contribute to the development of the disease. In this
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Figure 3: Comparison of cytokine and chemokine concentrations
in endometriotic lesions from different locations. A comparison
of the mRNA expression between endometriotic lesions from
different locations indicated that TNF𝛼 expression in the RVS was
significantly higher than expression in the ovarian lesions. IL-6
mRNAexpressionwas significantly higher in theRVS than either the
ovarian or the peritoneal lesions.There was no significant difference
between the lesions with any of the other cytokines. All values are
represented by mean ± SEM. ∗ < .05, ∗∗∗∗ < .0001.
study we found a significant increase in the expression of
RANTES and ENA-78 in the RVS lesions compared to the
matching eutopic tissue. RANTES production by ectopic
lesions recruits leukocytes [22], which then in turn stimulates
RANTES production [23] creating a feedback loop. Previous
studies support this result as RANTES correlates with deep
infiltrating endometriosis (DIE), which is most commonly
found in the RVS [24]. ENA-78 may also play a significant
role in the pathogenesis of endometriosis via the activation of
macrophages and the adhesion of endometriotic cells to the
underlying tissue [25]. Previous studies have shown that both
endometrial epithelial [26] and stromal cells [27] produce
significant amounts of ENA-78, which is stimulated by IL-
1𝛽, although this is the first evidence to indicate a significant
upregulation in production of ENA-78 by RVS lesions.
IL-8 has strong chemotactic properties for neutrophils
and T lymphocytes and is a potent angiogenic agent [28].
While numerous studies have shown an upregulation of
IL-8 in the peritoneal fluid of women with endometriosis
[29, 30] the source is not clear. An increase in peritoneal
macrophages may be responsible for a higher concentration
of IL-8, as would an increased production of IL-8 by the
endometriotic lesions themselves.. Previous evidence shows
that both cultured epithelial and stromal endometrial and
endometriotic cells produce IL-8 [26, 27], although one study
found that the ectopic tissue produced less IL-8 than the
eutopic tissue [31]. Another study on cultured epithelial and
stromal cells showed that IL-8 secretion is increased after
exposure to IL-1𝛽 [26].The lack of a significant difference for
IL-8 in this study may be a reflection of the need to stimulate
IL-8 production in endometriotic tissue.
TNF𝛼 mRNA expression was also significantly up-reg-
ulated in both the RVS and the peritoneal lesions compared to
those in their matching eutopic tissue. For IL-6 a significant
variation was only observed in the RVS lesion. TNF𝛼 has
an essential role in the inflammatory process. The primary
function of TNF𝛼 is to initiate a cascade of other cytokines
that can further stimulate a proinflammatory response. In
endometriosis it correlates with both the stage of the disease
[32], and the menstrual pain reported [33]. Consistent with
its early role in the inflammatory cycle it also stimulates
cytokines, such as IL-6. The increased expression of TNF𝛼 is
consistent with an important role for this cytokine in the early
pathogenesis of endometriosis that may be common for dif-
ferent types of lesions. The fact that IL-6 is only significantly
higher in RVS lesions may suggest that the inflammatory
pathway between these two lesions may diverge prior to this
point.
IL-6 is a multifunctional cytokine that can stimulate
cell proliferation [34] and angiogenesis [35] and is hormon-
ally regulated [36]. Different studies have shown both an
increase [14, 15] or no change in the peritoneal fluid of
women with endometriosis compared to women without
[37]. IL-6 production has previously been identified in
ectopic lesions, however results differ as to whether there
is a change in production once the tissue becomes patho-
logical. Some studies have found no significant difference
between eutopic endometrium and endometriotic tissue
fromovarian endometriosis [31], whereas others with ovarian
endometriosis only [38], or non-detailed locations, have
shown significant increases [39]. Furthermore, an in vitro
study from endometrial stromal cells isolated from chocolate
ovarian cysts showed a significant ability to produce IL-6with
production comparable to that of peritoneal macrophages
[40]. None of these previous studies however have addressed
the production of IL-6 in lesions from different locations.
A limitation of this study that should be mentioned is the
small number of samples available for the RVS region.This is
primarily due to the strict exclusion criteria for this study. As
evidence indicates that the use of GnRHa can have an effect
on the cytokine concentrations in the peritoneal fluid [41, 42]
we excluded all samples from women with previous GnRHa
use in the last 3months. As womenwith RVS lesions aremore
likely to experience painful symptoms and to have previously
sought treatment for endometriosis, a large proportion of
women presenting to our tertiary care facility with RVS
lesions had previous GnRHa or contraceptive use and thus
were excluded from the study.However, althoughwe only had
a small number of samples, the ability to use matched eutopic
and ectopic samples and our strict exclusion criteria should
provide more weight to these results. Further studies with
more samples should be performed to confirmour findings of
differential cytokine production from lesions from different
locations.
In conclusion, this study gives new insights in the produc-
tion of chemokines and cytokines in endometriotic lesions
from different locations and our results support the suppo-
sition that the RVS lesions are an intensely inflammatory
form of endometriotic lesions. Assessing lesions from dif-
ferent locations uniquely may be vital in understanding the
pathological changes of the disease and potentially for their
mode of treatment.
6 Mediators of Inflammation
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